Novotech Unveils 2024 Report on Global Gastric Cancer Clinical Trials and Cutting-Edge Therapeutics
4.9.2024 17:44:00 CEST | Business Wire | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Gastric Cancer- Global Clinical Trial Landscape (2024).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903559744/en/
This report details the current gastric cancer (GC) research environment as it continues to evolve, as well as offering key insights into the trends that are expected to extend into the near future. The report examines the global state of clinical trials, drug discovery, and emerging therapeutic strategies, while also highlighting the significant progress in understanding and treating GC, showcasing promising therapeutic pipelines with potential benefits for patients and associated organizations worldwide.
The Novotech research analyst team provides these expert reports monthly, highlighting key metrics on the current status of specific diseases and outlining future trends that may impact the development of treatments. This is provided completely free of charge.
Key takeaways from the report:
- Global Clinical Trials Surge
- Since 2019, over 2,000 clinical trials have been initiated globally, with the Asia-Pacific region leading the charge, accounting for 52% of all trials.
- Mainland China, in particular, stands out with 48% of the region's trials, reflecting the region's commitment to advancing GC research.
- North America and Europe also play crucial roles, contributing 29% and 15% of global trials, respectively.
- Innovative Drug Development
- The report identifies 228 drugs in various stages of development, highlighting a robust pipeline aimed at improving GC treatment outcomes.
- Notably, 11 drugs have already received approval, with 28 on the market, demonstrating the tangible progress made in recent years.
- The most significant focus is on targeted therapies and immunotherapies, with nearly 40% of ongoing Phase III trials investigating Programmed Cell Death Protein 1 (PD-1) antagonists.
- Advanced Therapeutic Strategies
- GC treatment strategies are increasingly shifting toward personalized medicine, with advancements in biomarker-directed therapies and molecular diagnostic techniques.
- Perioperative chemotherapy remains the standard for resectable GC, while ongoing research explores the benefits of combining targeted and immunotherapies in both perioperative and adjuvant settings.
- GC Therapies Attract Significant Funding
- From 2019 to 2023, GC research attracted substantial venture capital funding, totaling $7.4 billion globally.
- China and the United States are the leading recipients, securing $4.53 billion and $2.97 billion, respectively.
- This financial support underscores the global commitment to addressing the unmet needs of GC patients and advancing treatment options.
- Challenges and Opportunities
- The report highlights ongoing challenges, including the high cost of advanced treatments and the need for better patient selection and tailored therapies.
- However, significant opportunities exist in the form of liquid biopsies for detecting circulating DNA and the continued development of genetic and molecular profiling to personalize treatment approaches further.
- Market Leaders:
- The report identifies key players in the GC treatment market, including Pfizer, Roche, Merck & Co., Eli Lilly and Co., and Sanofi
- Strategic Insights:
- The report includes a SWOT analysis, demonstrating the effectiveness of current treatments in managing symptoms and improving quality of life, while also identifying areas where emerging techniques may offer improvements.
With ongoing clinical trials, innovative drug development, evolving therapeutic strategies, and continued investment of capital, the future of GC treatment looks promising.
For more information and to download the full report free of charge, please visit Novotech's website or contact our media relations team.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903559744/en/
Contacts
Toyna Chin
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release
Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and
Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release
Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co
Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release
Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom